These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 22760303)
1. A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer. Bal C; Chandra P; Kumar A; Dwivedi S Nucl Med Commun; 2012 Oct; 33(10):1039-47. PubMed ID: 22760303 [TBL] [Abstract][Full Text] [Related]
2. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241 [TBL] [Abstract][Full Text] [Related]
3. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850 [TBL] [Abstract][Full Text] [Related]
4. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. Bal CS; Kumar A; Pant GS J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929 [TBL] [Abstract][Full Text] [Related]
5. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E; N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127 [TBL] [Abstract][Full Text] [Related]
6. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial. Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716 [TBL] [Abstract][Full Text] [Related]
7. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. Rosário PW; Calsolari MR Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207 [TBL] [Abstract][Full Text] [Related]
8. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613 [No Abstract] [Full Text] [Related]
9. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974 [TBL] [Abstract][Full Text] [Related]
10. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824 [TBL] [Abstract][Full Text] [Related]
11. Differentiated thyroid carcinoma: Incremental diagnostic value of Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475 [TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. Silberstein EB J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976 [TBL] [Abstract][Full Text] [Related]
13. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868 [TBL] [Abstract][Full Text] [Related]
14. Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer. Yoo D; Ajmal S; Gowda S; Machan J; Monchik J; Mazzaglia P World J Surg; 2012 Jun; 36(6):1255-61. PubMed ID: 22430670 [TBL] [Abstract][Full Text] [Related]
15. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Lin JD; Kao PF; Chao TC Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241 [TBL] [Abstract][Full Text] [Related]
16. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer. Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282 [TBL] [Abstract][Full Text] [Related]
17. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan. Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773 [TBL] [Abstract][Full Text] [Related]
18. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257 [TBL] [Abstract][Full Text] [Related]
19. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial. Qu Y; Huang R; Li L Ann Nucl Med; 2017 Jan; 31(1):71-83. PubMed ID: 27757803 [TBL] [Abstract][Full Text] [Related]
20. Thyroid lobe ablation with iodine- ¹³¹I in patients with differentiated thyroid carcinoma: a randomized comparison between 1.1 and 3.7 GBq activities. Giovanella L; Piccardo A; Paone G; Foppiani L; Treglia G; Ceriani L Nucl Med Commun; 2013 Aug; 34(8):767-70. PubMed ID: 23652210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]